Clinical Trial Update: Gemcitabine Plus Docetaxel or Irinotecan in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating gemcitabine plus either docetaxel or irinotecan in patients with stage IIIB or stage IV non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Camptosar (irinotecan)
• Gemzar (gemcitabine)
• Taxotere (docetaxel)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED